# Study of NALIRIFOX in Advanced Unresectable Small Bowel Tumors

> **NCT06835387** · PHASE2 · RECRUITING · sponsor: **Tiago Biachi de Castria** · enrollment: 36 (estimated)

## Conditions studied

- Small Bowel Adenocarcinoma

## Interventions

- **DRUG:** Nanoliposomal irinotecan
- **DRUG:** Oxaliplatin
- **DRUG:** 5 fluorouracil
- **DRUG:** Leucovorin

## Key facts

- **NCT ID:** NCT06835387
- **Lead sponsor:** Tiago Biachi de Castria
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-30
- **Primary completion:** 2027-08
- **Final completion:** 2028-08
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2026-05-18

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06835387

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06835387, "Study of NALIRIFOX in Advanced Unresectable Small Bowel Tumors". Retrieved via AI Analytics 2026-08-15 from https://api.ai-analytics.org/clinical/NCT06835387. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*